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Transplantation: Indications and 
Strategies
Jean Jeanov Filipov and Emil Paskalev Dimitrov
Abstract
Kidney transplantation (KT) is the best renal replacement therapy in patients 
with chronic kidney disease (CKD). However, its success is limited due to insuf-
ficient number of donors worldwide and graft or patient loss. A major cause for 
poorer graft survival is donor-specific antibodies (DSAs). Therapeutic apheresis 
(TA) is a well-recognized option for increasing the donor pool by treating HLA-
sensitized patients and making AB0-incompatible KT possible. In addition, its use 
in patients with DSA has beneficial effect on graft survival. The aim of our review 
is to demonstrate the current knowledge on the use of TA (plasma exchange and 
immunoadsorption) in KT. In addition to the current guidelines, new trends in TA 
use prior to and after KT will be reviewed.
Keywords: therapeutic apheresis, kidney transplantation, desensitization, AB0 
incompatible transplantation, plasma exchange, immunoadsorption
1. Introduction
Kidney transplantation is a type of renal replacement therapy (RRT) in patients 
with end-stage renal disease (ESRD), which is associated with the best patient out-
comes. A major breakthrough was detected with the introduction of cyclosporine A 
in the immunosuppressive regimen. One-year survival improved further more with 
the use of novel immunosuppression (tacrolimus and mycophenolate), with graft 
survival rates for the first year after KT surpassing 95%. Despite the amazing results 
over the years, several problems are still unsolved.
A major obstacle to the success of KT is the shortage of donors worldwide [1]. 
An additional cause for donor insufficiency is the presence of donor-specific HLA 
antibodies (DSAs) in ESRD patients. HLA sensitization is caused mainly by blood 
transfusions, pregnancy, and previous organ transplantation. DSAs are associated 
with increased risk for acute rejection and poorer graft survival [2].
Another option to increase donor options could be AB0-incompatible transplan-
tation. However, in these cases the innate blood group barrier should be overcome 
in order to avoid hyperacute rejection.
Finally, long-term graft survival (at the fifth and tenth year after KT) is signifi-
cantly lower, compared to short-term one. One of explanations for this finding is 
the development of de novo DSA, which in turn are related to antibody-mediated 
rejection and poorer graft survival [3].
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Therapeutic apheresis (TA) is a method by which pathological elements of the 
immune system (cells, antibodies, and immune complexes) are being removed via 
extracorporeal system, thus influencing disease activity. Different TA techniques 
have been developed over the years. The most important ones in organ transplanta-
tion are plasma exchange (PEX) and immunoadsorption (IA).
1.1 Types of TA in kidney transplantation
1.1.1 Plasma exchange (PEX)
PEX is an invasive therapeutic method, separating plasma from blood cells. Thus 
pathogenic antibodies or other large molecules are removed and plasma is replaced 
by human albumin and/or fresh frozen plasma (FFP). The blood is pumped out of 
patient’s circulation, and is transferred to a separator (centrifugal bowl or hollow 
fiber membrane), separating plasma from blood cells. Afterward blood cells are 
pumped into patient’s vein and patient’s plasma is substituted by protein solution 
(human albumin and/or FFP). Generally, central venous catheter is used as vascular 
access, though arteriovenous fistulas and large peripheral veins can also be used. The 
mechanism of action of PEX is removal of pathogenic antibodies, substitution of 
plasma proteins, and modification of cell response. However, the procedure is asso-
ciated with albumin and fibrinogen loss, the latter being linked to increased bleed-
ing risk. Therefore, more selective techniques for antibody removal were developed. 
A subset of PEX is the selective PEX, in which a special membrane plasma separator 
with smaller pores is used. Its use in renal transplantation currently is limited.
1.1.2 Double filtration plasmapheresis (DFPP)
DFPP is a semi-selective separation technique, based on membrane PEX. After 
initial separation of plasma from blood cells, additional filtration of plasma is 
performed with different diameter of fiber pores, so that target protein fractions 
are filtered and the rest are returned into the circulation. This technique showed 
up to 70% reduction in albumin loss after the procedure lower risk for infec-
tions and allergic reactions. The method was used initially for ABo-incompatible 
 transplantation [4].
1.1.3 Cryofiltration
The technique was designed to remove cryoglobulins in several immune dis-
eases. After plasma is initially filtrated, it is cooled to 4°C. This causes precipita-
tion of cryoglobulins and they do not pass the second membrane. Afterward, the 
cooled plasma is warmed to body temperature again and is returned to the patient. 
The method was used in AB0-incompatible transplantation and HLA-sensitized 
patients. However, further studies are needed to incorporate cryofiltration in 
transplantation practice [5, 6].
1.1.4 Selective adsorption, immunoadsorption
In selective adsorption the plasma is filtered at the first step of the procedure, 
and at the second stage the initial filtrate runs through pre-arranged immuno-
sorbents. Thus specific antibodies can be selectively removed, whereas albumin 
and clotting factors are returned to the patient. There are two types of selective 
adsorption—immunoadsorbtion (IA) and selective plasma adsorption. In IA either the 
plasma runs through column bearing antigens directed against certain antibody, 
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or antibodies against certain plasma constituents. In selective plasma adsorption 
plasma components are removed by binding to ligands other than antibodies and 
antigens (e.g., heparin and dextransulfate in LDL adsorption).
Practically only IA is used in transplantology. There are different IA techniques 
according to IA devices [7]:
1. IA using immobilized antibodies—sheep polyclonal anti-human IgG antibod-
ies are used to remove IgG antibodies from plasma
2. IA using immobilized antigens and synthetic epitopes—the IA columns 
contain only immobilized antigens/epitopes, thus removing the pathogenic 
antibodies only. This method is the most specific one.
3. IA using staphylococcal protein A—IA columns containing immobilized 
Staphylococcal protein A, which effectively clears IgG types 1,2, and 4 by 
 binding their Fc portions
1.1.5 Extracorporeal photopheresis (ECP)
ECP is a method, in which white blood cells are separated from plasma and 
are being treated extracorporeally with 8-methoxypsoralen (8-MOP) followed 
by exposure to ultraviolet A (UVA) light. The treated cells are then returned into 
patient’s circulation. Initially used in the treatment of T-cell lymphoma, its indica-
tions have expanded in solid organ transplantation (heart, lung, and kidney). In 
renal transplantation ECP was used in recurrent and refractory rejection, as well as 
in antibody-mediated chronic rejection with conflicting results [7].
1.2 TA immunosuppression in KT
PEX and IA can remove the already produced antibodies, but they cannot 
influence the antibody production. However, after TA a rise in antibody formation 
and increase in B-cell proliferation occurs [8]. Therefore, TA should be coupled 
with adequate immunosuppression. In TA prior to or after renal transplantation 
the most widely used immunosuppressive medications are the biological agents—
Thymoglobulin (ATG, dose 1–1.5 mg/kg, different protocols exist), Rituximab 
(standard dose 375 mg/m2/weekly for 2–4 weeks) and intravenous immunoglobulins 
(IVIG, 100 mg/kg after each procedure). Eculizumab is also taken into consideration 
in high-risk patients prior to and after KT. Its effectivity is fully recognized in post-
transplant atypical hemolytic uremic syndrome (aHUS). Further trials are needed to 
evaluate the exact place of this monoclonal drug in transplantation [9]. In addition, 
as the KT in sensitized patients is regarded as high-risk procedure, anti-CD25 agents 
can also be applied.
1.3 Classification of TA according to effectivity
The beneficial effect of TA is difficult to assess due to the relatively low number 
of randomized controlled trials (RCTs). According to the American Society for 
Apheresis (ASFA) the indications for TA have been classified into four categories, 
according to the possible beneficial effect of the procedure [10]:
• Category 1—Disorders for which apheresis is accepted as first-line therapy, 
either as a primary standalone treatment or in conjunction with other modes of 
treatment, for example, recurrent focal segmental glomerulosclerosis (FSGS).
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• Category 2—Disorders for which apheresis is accepted as second-line 
therapy, either as a standalone treatment or in conjunction with other modes 
of  treatment, for example, antibody-mediated rejection (AMR) in AB0-
incompatible KT.
• Category 3—Optimum role of apheresis therapy is not established. Decision-
making should be individualized—for example, HLA desensitization in 
deceased donation in AB0-compatible transplantation.
• Category 4—Disorders in which published evidence demonstrates or suggests 
apheresis to be ineffective or harmful—for example, lupus nephritis.
2. TA prior to renal transplantation
The presence of antibodies against donor HLA alleles significantly increases 
the risk for acute rejection and graft survival. Similarly, AB0-incompatible KT is 
associated with hyperacute rejection due to the presence of antibodies against A-/B-
antigens on the surface of vascular endothelial cells. Therapeutic apheresis plays a 
key role in reducing the titers of pathogenic antibodies, thus significantly improv-
ing graft survival, reduces the risk for graft rejection, and increases the chances for 
successful KT.
2.1 AB0-incompatible (AB0i) KT
The antigens, associated with AB0 blood groups are expressed not only on the 
red blood cell’s membrane, but also on the surface of the endothelial cells, making 
the A-/B-glycolipids one of the most important antigens, related to transplantation 
immunology. The naturally circulating antibodies against the above-mentioned 
AB0 antigens in AB0i renal transplantation lead to hyperacute rejection, severe 
endothelial damage, and thrombosis, which finally leads to graft loss within 
minutes after revascularization. Therefore, AB0 incompatibility is a major obstacle 
to successful KT. It was estimated, that its treatment can effectively increase the 
numbers of living donors by up to 30%. In addition, the current protocols for AB0i 
KT demonstrate comparable success to AB0-compatible KT [11].
Different protocols for desensitization in AB0i KT exist, generally most of them 
aim for target post-procedure isoagglutinin titers ≤1:8 (Table 1, [12–14]). In the 
early stages of AB0i KT splenectomy was performed in addition to PA. However, 
this practice was abandoned due to the risk for infectious complications and 
immunosuppressive agents were introduced in everyday practice. In cases, in which 
PEX was used, substitution with albumin or FFP is needed. FFP should be both 
donor and recipient AB0 compatible [10]. The number of procedures varies accord-
ing to baseline isoagglutinin titers. The most widely used TA techniques are PEX 
and selective IA, though DFPP can also be taken into consideration (Table 1). As TA 
markedly improves prognosis in AB0i KT, it is regarded as first-line therapy in AB0i 
recipient-donor pairs (ASFA category 1) [10].
2.2 HLA desensitization
The presence of antibodies against the HLA alleles of the donor prior to KT is 
another obstacle for the success of the procedure. The presence of donor-specific 
anti-HLA antibodies (DSAs) cause graft loss due to antibody-mediated rejection 
(AbMR) and is also referred as HLA-incompatible (HLAi) KT. At higher titers DSA 
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cause hyperacute AbMR, whereas lower titers result in acute or chronic AbMR 
[7]. The major causes for HLA sensitization are previous transplantation, blood 
transfusion, or pregnancy.
Due to the increased immunological risk, sensitized candidates remain sig-
nificantly longer on the waiting list. It was estimated, that approximately 30% of 
the candidates for KT have detectable anti-HLA antibodies and half of them are 
highly sensitized, being sensitized to more than 80% of the possible HLA alleles. 
Desensitization protocols, by which undetectable DSA titers and negative cross-match 
are achieved, significantly improve graft survival, especially in living donation.
2.2.1 HLA desensitization in AB0-compatible KT, deceased donors
In deceased donor KT (DDKT) there are conflicting data considering the effec-
tivity of TA. In patients on the waiting list, attempts have been made to perform 
HLA desensitization, with unclear benefit (Table 2, [15–21]). However, the pro-
longed exposure to immunosuppressive agents should be taken into consideration.
More studies have been performed in TA and DDKT in the perioperative set-
ting. Generally, the aim is negative cross-match to be achieved prior to KT. Different 
protocols were suggested, using PEX/IA, accompanied by immunosuppressive agents 
(rituximab, IVIG, ATG). Though short-term results were encouraging, long-term ones 
are still conflicting [21]. AbMR and T-cell rejection had higher incidence in DSA/+/
kidney transplant recipients (KTRs), especially in those with higher mean intensity 
fluorescence (MFI) [19, 21]. Therefore, higher pre-transplant DSA titers have poorer 
prognosis, despite current desensitization protocols in deceased donors. Currently, 
due to the insufficient data on the use of TA in HLA desensitization in DDKT and the 
conflicting results it falls into category 3 of the latest ASFA guidelines [10].
Target 
antibody 
level at 
KT day
TA strategy Immunosuppression Results Reference
1:8 initial 
phase, 
later 1:32
PEX 30 ml/kg/
session, alternate 
days, start 7 days 
prior to KT
RTX 200 mg on day 
(−15); IVIG 5 g after 
each PEX (total 10–25 g), 
Thymoglobulin—two doses, 
total 3 mg/kg
1 year graft and 
patient survival 
97.8%
Ray DS 
et al.
1:8 DFPP start: 7 days 
prior to KT, 
alternate days, 
performed post KT
RTX at day −14
Tac and mycophenolate at 
day (−7)
Graft survival 
87%, patient 
survival 93%, 
post-transplant 
infection rate 13%
Jha PK et al
1:8 Antigen-specific IA
Start: day (−6)
four sessions, 
treatment volume: 
two plasma volumes
After KT three more 
sessions within nine 
days
RTX 375 mg/m2—day (−14)
Triple immunosuppression 
(Tac, MMF, Prednisolone)
IVIG 0.5 g/kg after final IA
All patients 
had good graft 
function during 
the follow-up
Tydén G 
et al
TA—therapeutic apheresis, PEX—plasma exchange, DFFP—double filtration plasmapheresis, IA—
immunoadsorption, RTX—rituximab, IVIG—intravenous immunoglobulin, Tac—tacrolimus, MMF—
mycophenolate mofetil.
Table 1. 
Desensitization protocols in AB0 incompatible kidney transplantation.
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TA on the waiting list
Study design TA strategy Immunosuppression Results Reference
IA and 
immunosuppression 
in HLA-sensitized 
ESRD patients
IA Cyclophosphamide + 
steroids
Unclear benefit, 
safe procedure
Hiesse C. et al
PEX and 
immunosuppression 
in HLA-sensitized 
ESRD patients
PEX—12 
procedures
Cyclophosphamide 
+ steroids on the first 
day of PP, tapered 
till KT
9 out of 23 lost 
grafts in the first 
2 months post KT, 
59% graft survival 
at fifth year 
post-transplant
Alarabi A. 
et al.
Peritransplant TA
PEX in DDKT, 
positive cross-
match, aiming 
negative one
PEX—1 
procedure
RTX First year graft 
survival 92.4%, 
patient survival 
95.8%
Morath C 
et al.
Desensitization 
IVIG vs. IVIG/RTX/
PEX, negative cross-
match on KT day
Short-term results
PEX—9 
procedures, 
alternate days 
post KT
IVIG 2 g/kg on days 
0,2,42, 63;
RTX days 2 and 22
Better GFR and 
greater DSA-MFI 
decrease in IVIG/
RTX/PEX group
Loupy et al.
Desensitization with 
IVIG/RTX/PEX 
MFI˃3000 vs. MFI 
500–3000,
both groups with 
negative cross-
match on KT day
Long-term results
PEX—9 
procedures, 
alternate days 
post KT
IVIG 2 g/kg on days; 
0,2,42, 63
RTX days 2 and 22
Similar GFR in 
both groups;
lower incidence of 
T-cell rejection in 
MFI 500–3000
Amrouche L 
et al.
Desensitization 
in DDKT broadly 
sensitized patients;
KT performed after 
negative cross-
match achieved
IA 
(staphylococcal 
protein A) 
initial volume 
6 L, later 2–3 
plasma volumes;
first session—
immediately 
before KT;
after KT—IA 
every 1–3 days, 
up to 7 weeks
ATG Similar graft and 
patient survival 
compared to 
DSA/−/ at third 
year post KT
Bartel G. 
et al.
The Vienna 
group
Extended previous study of the Vienna group, no change in protocol Poorer graft 
survival compared 
to DSA/−/ at third 
year post KT, 
higher incidence of 
AbMR in DSA/+/, 
higher MFI was 
associated with 
higher risk for 
rejection
Schwaiger E 
et al.
The Vienna 
group
TA—therapeutic apheresis, PEX—plasma exchange, IA—immunoadsorption, RTX—rituximab, IVIG—
intravenous immunoglobulin, KT—kidney transplantation, DDKT—deceased donor kidney transplantation, MFI—
mean intensity fluorescence, ATG—thymoglobulin, DSA—donor-specific antibodies, AbMR—antibody-mediated 
rejection, GFR—glomerular filtration rate, ESRD—end-stage renal disease.
Table 2. 
HLA desensitization protocols in AB0-compatible deceased donors kidney transplantation.
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2.2.2 HLA desensitization in AB0-compatible KT, living donors
HLA desensitization is far more important and more effective in living donor 
kidney transplantation (LDKT). A multicenter study demonstrated that KTRs with 
HLAi LDKT have better survival than patients on the waiting list without being 
transplanted or those on the waiting list with deceased donor KT. The benefit was 
significant in the short and in the long run [22].
The most used TA techniques in LDKT desensitization protocols are PEX and 
IA. Usually 4–8 sessions of PEX are performed prior to KT on alternate days. In 
most of the studies low-dose IVIG (10–150 mg/kg) was infused after each PEX, 
though the IVIG can be applied at the end of the series too [10]. Post-transplant 
PEX procedures were also performed (5–9 sessions) [22, 23]. In some studies myco-
phenolate and tacrolimus were added to the protocol 14 days prior to KT [23]. RTX 
was also used in certain protocols, forming a triple regimen—PEX/low-dose IVIG/
RTX. Though an overall AbMR rate between 30 and 40% was detected, graft and 
patient survival reached up to 93 and 95% respectively at the first year [10, 24].
IA is the other most widely used TA modality in LDKT desensitization. It is 
coupled with RTX ± IVIG and graft survival rates reach up to 100% at the second 
year. Pre-transplant oral immunosuppressive agents could be used (tacrolimus + 
mycophenolate + steroids) and ATG/Basiliximab induction therapy as well [25].
2.3 Desensitization in combined HLAi/ABOi KT
In the rare setting of both HLAi and AB0i KT desensitization using PEX/IA 
plays a key role. A study using TA (PEX or specific/non-specific IA), combined with 
IVIG, two doses of RTX (375 mg/m2) and Tacrolimus (0.2 mg/kg started 10 days 
prior to KT) demonstrated excellent graft and patient survival [26].
3. TA after renal transplantation
The major indications for TA after successful KT are AbMR and recurrent or de 
novo glomerular disease.
3.1 TA in AbMR
3.1.1 Acute AbMR
In HLA-desensitized patients AbMR ranges between 30 and 40% post-
transplant, despite successful desensitization prior to KT. However, acute AbMR 
can occur in up to 10% after KT due to de novo DSA. The diagnosis is based on 
the presence of DSA, C4d deposition in peritubular capillaries, and evidence of 
tissue injury (typically associated with neutrophil/macrophage infiltration) [27]. 
However, AbMR without C4d deposition is also possible according to the BANFF 
criteria [28]. Acute AbMR is categorized into early (within 6 months after KT) and 
late (more 6 months after KT). Both types are associated with poorer graft survival; 
however, early acute AbMR is more responsive to the current treatment protocols.
PEX and IA play a key role in acute AbMR treatment and fall into ASFA cat-
egory 1 [10]. The protocol consists usually of at least five TA procedures, coupled 
with IVIG infusion (total does 1–2 g/kg, 100–200 mg/kg after each procedure). 
In addition, RTX was tested as immunosuppressive agent, added to TA + IVIG 
combination. The results for RTX-based protocols so far are inconsistent, as some 
studies indicate benefit from the triple combination, whereas others fail to establish 
positive effect on short-term or long-term graft survival [29, 30].
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Other preparations were tested in combination to TA as well: Bortezomib, com-
plement component 1 (C1)—inhibitor and eculizumab (C5a inhibitor) currently 
with unclear benefit, indicating the need for further research in this field [31].
3.1.2 Hyperacute AbMR
Hyperacute AbMR presents with cyanosis and anuria, occurring minutes after 
revascularization of the graft, and is caused by pre-formed antibodies against the 
graft (AB0 incompatibility, HLA-DSA, antibodies against endothelial and mono-
cyte antigens). It is currently a rare finding due to improved pre-transplant immu-
nological evaluation. Histologically small vessel endothelial damage is detected, 
as well as thrombosis and neutrophil infiltration. There is no treatment, the only 
option is nephrectomy [32].
3.1.3 Chronic AbMR
Chronic AbMR is diagnosed by the presence of donor-specific antibodies, 
C4d deposition in peritubular capillaries, and evidence of chronic tissue injury. 
Chronic tissue injury encompasses duplication of the glomerular basement mem-
brane (GBM), multilamination of the peritubular capillary basement membrane, 
arterial intimal fibrosis without elastosis, and interstitial fibrosis with tubular 
atrophy [27]. Though different TA techniques have been tested in chronic AbMR, 
including ECP, the procedure is generally ineffective due to the chronic histology 
findings [27].
3.1.4 De novo DSA and subclinical AbMR
The detection of de novo DSA after KT is associated with poorer transplant 
outcomes due to higher incidence of chronic allograft nephropathy (CAN) [33]. 
Subclinical AbMR is main cause for CAN in these cases. It presents with the typical 
histology and serology for AbMR, without significant changes in the laboratory 
and clinical findings. A recent study failed to demonstrate significant beneficial 
effect from two sessions of DFPP+RTX in subclinical AbMR. In this paper, patients 
with de novo DSA without data for rejection, who received no treatment, were 
also evaluated. In the follow-up period no significant changes in graft function and 
proteinuria in this subgroup occurred [34]. Therefore more clinical trials are needed 
to evaluate the importance of TA in subclinical AbMR and in de novo DSA without 
rejection.
3.1.5 TA in non-DSA post KT
The importance of non-DSA post KT is currently unclear. Though certain 
studies demonstrate association between non-DSA and acute AbMR, others fail to 
establish such relationship, even at MFI up to 10,000 [35, 36]. Additional trials are 
needed to fully evaluate the significance of non-DSA and the possible treatment 
methods in the future.
3.2 TA in recurrent disease
3.2.1 Recurrent focal segmental glomerulosclerosis (FSGS)
FSGS is a disease, in the pathogenesis of which an unidentified plasma factor 
plays a key role by increasing glomerular barrier permeability and causing podocyte 
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injury. The presence of such factor is further supported by the fact, that primary 
FSGS has high recurrence rate after KT—up to 50% after the first KT and up to 
100% in repeated transplantations [10]. Though the molecule has not been defi-
nitely identified, a considerable research has been performed in order to evaluate 
the role of TA in the treatment of FSGS.
TA is regarded in the treatment of primary FSGS only after treatment with ste-
roids and calcineurin inhibitors (CNI) have failed. However, PEX/IA is considered 
as first-line treatment in recurrent FSGS after KT, as it leads to complete or partial 
remission in more than 50% of the KTRs [10]. They usually combined with immu-
nosuppression—high-dose steroids, cyclophosphamide, higher doses of CNI and 
RTX. The needed number of procedures to achieve effective control of the disease 
by evaluating proteinuria is highly variable.
In recurrent FSGS PEX/IA are performed daily/every other day. The treatment 
should be started as early as possible in order to avoid progression of the disease. 
Proteinuria is the only marker that is used to assess the effect from the treatment. 
Treatment may have longer duration in order to avoid new episodes. Unfortunately, 
no predictors for TA effectivity in recurrent FSGS exist [10]. In addition, pre-
transplant treatment failed to prevent recurrence of the disease [37].
Lipoprotein apheresis (LA) was assessed as a third TA modality in the treat-
ment of FSGS. In LA lipoprotein particles are selectively removed from blood. The 
possible explanation for the benefit of this method is reducing the lipotoxic effect of 
hypercholesterolemia on podocyte function. Usually it is performed twice per week 
for 3 up to 6 weeks [10]. Currently LA is approved for primary/recurrent FSGS only 
in the USA.
3.2.2 Immunoglobulin A (IgA) nephropathy/Henoch-Schönlein Purpura
IgA nephropathy recurrence rate varies between 9 and 53% and is associated 
with poorer graft survival. Different predictors have been identified: crescentic 
forms of the disease, earlier onset of the primary disease, serum IgA levels, and 
steroid withdrawal after KT [38].
PEX did not prove to be effective in the treatment of primary IgA nephropathy 
[10, 39]. Indeed, predominantly cases with rapidly progressive crescentic IgA 
were evaluated without significant beneficial effect. The data for PEX treatment 
after KT are insufficient; therefore TA is generally not prescribed in recurrent 
IgA nephropathy. Similarly to IgA nephropathy, TA has no significant efficacy in 
Henoch-Schönlein Purpura.
3.2.3 Recurrent membranous nephropathy (MN)
Primary (idiopathic) membranous nephropathy (IMN) is characterized with the 
presence of autoantibodies against the podocyte localized phospholipase A2 recep-
tor (anti-PLA2R). Currently, the recognized treatment options are cycling regimen 
(steroids/alkylating agent), CNI, or RTX. A single study demonstrated significant 
improvement from the combination of PEX + IVIG + RTX in resistant to conserva-
tive treatment (steroids/cyclophosphamide or CNI or RTX) IMN [40]. In this study, 
four PEX procedures were performed, coupled with a dose of 20 g IVIG and single 
dose RTX 375 mg/m2.
The recurrence rate of IMN reaches 50%. High titers of anti-PLA2R were 
found to be a risk factor for recurrence after KT. Generally, switching from mTOR 
inhibitor to CNI is recommended, as well as use of RTX; alkylating agent should be 
avoided due to the risk for too potent immunosuppression [41]. Unfortunately, the 
role of TA in recurrent IMN is unclear and further research in this sphere is needed.
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3.2.4 Recurrent membranoproliferative glomerulonephritis (MPGN)
Primary MPGN has two major types according to its pathogenesis: immune 
complex mediated and complement mediated. The new classification enables not 
only the better understanding of the disease, but also evaluates better the risk for 
recurrence after KT.
Immune complex-mediated MPGN is characterized by the glomerular deposi-
tion of polyclonal or monoclonal immunoglobulins. It is believed that the types 
and patterns of immunoglobulins may influence post-transplant characteristics of 
recurrent MPGN. For instance, IgG3k and IgG3λ deposits are linked to earlier recur-
rence and faster graft loss [41].
In the complex-mediated MPGN there are C3 glomerular deposits without 
immunoglobulin ones. It is known also as C3 glomerulopathy and consists of two 
entities—C3 glomerulonephritits and dense deposits disease (DDD). The two 
diseases have similar pathogenesis and clinical course. A recurrence rate up to 67% 
was reported for both diseases; DDD tended to recur later after KT and in both 
types graft failure was 50% [41, 42].
The suggested treatment so far includes PEX and immunosuppression—cyclo-
phosphamide, RTX or eculizumab. However, the published studies are small and 
the results are inconsistent. Therefore larger trials are needed to evaluate the effec-
tiveness of TA and the concomitant immunosuppressive agents in post-transplant 
MPGN [41].
3.2.5  Complement-mediated thrombotic microangiopathy (cmTMA, atypical 
hemolytic uremic syndrome)
Complement-mediated thrombotic microangiopathy (cmTMA), previously 
known as atypical hemolytic uremic syndrome is a life-threatening condition, 
which is caused by over-activation of the alternative pathway of the complement 
system. It presents with thrombocytopenia, microangiopathic hemolytic anemia, 
acute kidney injury, minimal to absent neurologic involvement, and fever. Over-
activation is caused by genetic mutations causing impaired function of the alterna-
tive pathway inhibitors (factor H, membrane cofactor protein, and factor I) or 
overexpression of activators (factor B and complement component C3). Anti-Factor 
H autoantibodies can also cause cmTMA.
Generally, the disease’s recurrence rate peaks up to 75% and is a significant 
predictor for poorer graft survival—90% of these grafts are lost within the first 
post-transplant year as the pathogenic serum proteins persist after the operation. 
However, membrane cofactor protein-associated cmTMA recurs significantly less—
up to 20% after KT, with better graft survival due to the normal graft membrane 
proteins [43].
Initially, cmTMA was treated with daily PEX and immunosuppression. The 
recommended substitution fluid was FFP or FFP/albumin. However, with the intro-
duction of Eculizumab in the treatment of the disease, the role of PEX is uncertain, 
as studies failed to demonstrate any advantage of PEX + Eculizumab vs. Eculizumab 
only [44]. PEX is reserved as first line therapy only in the presence of anti-Factor H 
autoantibodies, combined with immunosuppression [10].
3.2.6 Thrombotic thrombocytopenic purpura (TTP) after KT
TTP is TMA, characterized by similar clinical and laboratory findings as in 
cmTMA. However, it is more common in adults, presents with more pronounced 
thrombocytopenia, usually severe neurological impairment, and varying degree 
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of renal insufficiency. In the post-transplant setting TTP is associated with CNI/
mTOR inhibitors treatment, AbMR, viral infections, and ischemia reperfusion 
injury [45].
The key point in the treatment is correction of immunosuppressive treatment or 
treatment of the underlying condition. PEX can be included in the therapy, though 
the current data fail to demonstrate clear benefit from the procedure. Eculizumab 
proved to be more effective in these cases [46]. AbMR-associated TMA is usually 
treated with PEX + IVIG; RTX and Eculizumab can also be added to the treatment, 
especially in resistant to the standard PEX treatment cases [47, 48].
3.2.7 ANCA-associated vasculitis
The recurrence rate of ANCA-associated vasculitis is relatively low—approx. 
10%. In these cases treatment as per general population is recommended.
Usually PEX is used in ANCA vasculitis in the native kidney in cases of rapidly 
deteriorating kidney function, diffuse alveolar hemorrhage, and serum creatinine 
above 5.7 mg/dl (504 μmol/L) [10, 39]. In recurrent ANCA vasculitis after KT the 
indications for TA are similar, usually the procedures are combined with immuno-
suppressive agents—steroids + cyclophosphamide or steroids + RTX [49]. Generally 
7–12 procedures are needed. In alveolar hemorrhage the substitution fluid for PEX 
is FFP in order to avoid further increase in bleeding [10].
It is recommended in patients with ANCA vasculitis and end-stage renal disease 
transplantation to be delayed until a complete extrarenal remission for at least 
12 months is achieved. However, ANCA-positive patients with extrarenal remission 
can be transplanted [39].
3.2.8 Recurrent/de novo anti-glomerular basement membrane (GBM) disease
Anti-GBM disease is usually caused by autoantibodies against the α3 chain of 
type IV collagen. The disease recurs in up to 50% of the cases post-transplant; the 
presence of detectable auto-antibodies’ titer prior to KT is a well-established factor 
for recurrence. Therefore a period of at least 6 months of undetectable anti-GBM 
antibodies is recommended prior to KT [39].
De novo anti-GBM disease post-transplant usually develops in cases with Alport 
syndrome. In this clinical setting, the patients have impaired synthesis of collagen 
4, with missing chains from α3 to α5 (usually α5), due to genetic mutations. After 
successful KT the graft expresses the normal α chains, which can trigger immu-
nological response against these normal structures. De novo anti-GBM disease is 
detected in approx. 15% of the Alport patients after KT [7].
De novo anti-GBM disease presents with the symptoms of the disease in native 
kidneys. However, the recurrent form can present with subclinical course [50].
Generally, treatment is performed as per native kidneys’ anti-GBM disease. 
Therapy should be initiated as early as possible. PEX is performed daily or every 
other day, anti-GBM antibody titers should be monitored and the procedure should 
be performed until the autoantibodies are undetectable (approx. 10–14 sessions). 
PEX is combined with steroids and cyclophosphamide; the role of RTX is currently 
unclear [10, 39].
3.2.9 Catastrophic antiphospholipid syndrome (cAPS)
Catastrophic antiphospholipid syndrome (cAPS) is acute life-threatening 
condition, associated with multiple thromboses in at least three systems within days 
or weeks, due to the presence of antiphospholipid antibodies (lupus anticoagulant, 
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anticardiolipin, and anti-β2-glycoprotein I). The presence of cAPS is an indica-
tion for PEX. The procedure should be performed in combination with steroids 
± IVIG and anticoagulants. This triple combination proved to be effective in 
cAPS. However, cyclophosphamide, eculizumab, and RTX were also used in the 
treatment [51]. PEX in cAPS is performed daily or every other day, substitution 
fluid is usually FFP or FFP + albumin [10].
The data for cAPS after KT are limited. The presence of antiphospholipid anti-
bodies is a recognized risk factor for cAPS and anti-phospholipid syndrome (APS) 
recurrence [7]. A paper demonstrated that the use of Eculizumab can prevent post-
transplant cAPS [52]. Barbour et al. demonstrated partial graft function improve-
ment in patient with post-transplant cAPS, treated with PEX (28 procedures over 
49 days), IVIG, and anticoagulation [53]. Further research in the field is needed, as 
the number of patients with APS/cAPS is small, especially those after KT.
4. Conclusions
TA has a well-established role in desensitization protocols prior to KT and treat-
ment of AbMR in the post-transplant period. However, its place in the treatment 
of recurrent/de novo post-transplant glomerular disease is not fully understood 
due to the relatively small number of patients, insufficient controlled clinical 
trials, and different immunosuppressive agents used alongside with the procedure. 
In addition, the different TA modalities further complicate the assessment of TA 
effectivity. A multicenter approach could give better insight into TA role after renal 
transplantation and optimize its use in everyday clinical practice.
© 2020 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
of the Creative Commons Attribution License (http://creativecommons.org/licenses/
by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, 
provided the original work is properly cited. 
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